Author/Authors :
M.W. Saville، نويسنده , , J. Lietzau، نويسنده , , J.M. Pluda، نويسنده , , W.H. Wilson، نويسنده , , R.W. Humphrey، نويسنده , , E. Feigel، نويسنده , , S.M. Steinberg، نويسنده , , Michael S. Broder، نويسنده , , R. Yarchoan، نويسنده , , J. Odom، نويسنده , , I. Feuerstein، نويسنده ,
Abstract :
We investigated whether paclitaxel was active in AIDS-associated Kaposiʹs sarcoma. We gave 135 mg/m2 intravenously over 3 hours every 21 days. Follow-up is available on the first 20 patients, most of whom had advanced Kaposiʹs sarcoma and severe immuno-compromise. Neutropenia was the most frequent dose-limiting toxic effect; novel toxic effects included late fevers, rash, and eosinophilia. Creatinine increased in 2 patients and 1 patient had cardiomyopathy. There were 13 partial responses (65%, 95% Cl 41-85%). All 5 patients with pulmonary involvement responded. Paclitaxel appears to be active against Kaposiʹs sarcoma as a single agent. Further studies, including a randomised trial, are warranted.
